Announcement of the Split of Showa Denko Materials’ Regenerative Medicine Business Sector (Yokohama Site)
June 02, 2021
Showa Denko Materials Co., Ltd.
Showa Denko Materials Co., Ltd. (President and CEO: Hisashi Maruyama; hereinafter “Showa Denko Materials”) announces the transfer of its Regenerative Medicine Business Sector Yokohama Site (hereinafter “Yokohama Site”), which provides contract manufacturing services for regenerative medicine products, to its wholly owned subsidiary Minaris Regenerative Medicine Co, Ltd. (hereinafter “MRJ”) through a company split, effective August 1, 2021.
The Showa Denko Materials Group operates a global regenerative medicine business at five facilities – one in Japan (Yokohama City, Kanagawa Prefecture), three in the United States (one in Mountain View, California and two in Allendale, New Jersey), and one in Europe (Ottobrunn, Bavaria, Germany). In September 2020, the Group’s regenerative medicine companies in the United States and Germany changed their names to Minaris Regenerative Medicine, LLC and Minaris Regenerative Medicine GmbH, respectively. With Yokohama Site taken over by MRJ, all the manufacturing facilities in Japan, the United States, and Europe will be unified under the name “Minaris Regenerative Medicine.” The Showa Denko Materials Group will promote this name as the global brand of its contract manufacturing services for regenerative medicine products.
The global system of the Showa Denko Materials Group provides contract manufacturing services in Japan, the United States, European countries, and regions where many regenerative medicine products are developed by its customers, namely, pharmaceutical manufacturers. The integration of regenerative medicine business operations arising from the transfer of Yokohama Site to MRJ will allow the Group to strengthen its system capable of more quickly sharing regulatory information on the manufacture of regenerative medicine products in different regions and timely delivering supplies of products that meet customer demands and regulatory requirements in each region.
The Showa Denko Materials Group also plans to introduce “Minaris” to the corporate names of the relevant group companies in its medical business,※ starting in July 2021. (The Group’s life sciences business consists of the regenerative medicine business and medical business sectors.) Under the unified brand name, the Group’s life sciences business will work in full coordination with its facilities to contribute to the health and well-being of people around the world.
- ※ The Showa Denko Materials Group’s medical business develops, manufactures, and sells in vitro diagnostics and medical devices used for measurement thereof.
1. Outline of the parties to the company split (as of June 2, 2021)
| Splitting Company | Successor company | |
|---|---|---|
| (1) Name | Showa Denko Materials Co., Ltd. | Minaris Regenerative Medicine Co., Ltd. |
| (2) Address | 1-9-2, Marunouchi, Chiyoda-ku, Tokyo | Shibusawa ABC building 1, 1 Ebisu-cho, Kanagawa-ku, Yokohama-shi, Kanagawa |
| (3) Name of representative | Hisashi Maruyama, President and CEO | Hiroto Bando, President(takes office on August 1 (planned)) |
| (4) Principal lines of business | Manufacture, processing, and sale of functional materials and advanced components and systems | Contract process development and manufacturing for regenerative medical products |
| (5) Capital | 15,454 million yen | 310 million yen |
| (6) Established | October 10, 1962 | January 4, 2021 |
| (7) Major shareholders and shareholding ratio | HC Holdings K.K. 100.0% | Showa Denko Materials Co., Ltd. 100.0% |
2. Schedule of the company split
Conclusion of the company split contract: May 14, 2021
Scheduled execution of the company split (effective date): August 1, 2021
For further information, contact
Public Relations Group, Brand Communication Department